FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...
Data from patients who underwent curative resection of stage I, II, or III MSI colon cancer in 2014-2021 (model training cohort, 384 patients, 33 events; median follow-up, 38.8 months) were ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...
The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...
Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to ...
Biocartis Group NV received premarket approval from the U.S. FDA for its Idylla Cdx MSI test, developed in partnership with Bristol Myers Squibb Co., to help in the diagnosis and treatment of ...
Primary efficacy endpoint readout expected in mid-2025 Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses ...
Three separate announcements revealed advancements in oncology: FDA clearance for ArteraAI Breast, a GSK-Halozyme agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results